About the Ozempic (Semaglutide) Shortage in 2022 and 2024

Overview

This page summarizes key information regarding the ongoing Ozempic (semaglutide) shortage as reported by the Therapeutic Goods Administration (TGA). Novo Nordisk, the supplier of Ozempic, has advised that supply limitations will persist throughout 2023 and 2024. Here’s what you need to know:

Current Supply Situation

Novo Nordisk has informed the TGA and the Ozempic Medicine Shortage Action Group that the supply of Ozempic will be constrained due to a surge in demand, particularly for the low-dose (0.25/0.5 mg) version. This increase is largely due to off-label prescribing for weight loss, which is not an approved use by the TGA.

Guidance for Prescribers and Pharmacists

The TGA, in consultation with the Medicine Shortage Action Group (MSAG), advises the following:

• Prescribers: Avoid starting new patients on Ozempic unless absolutely necessary. For those already on Ozempic, consider alternative treatments as continuous supply is not guaranteed.
• Pharmacists: Prioritize the limited Ozempic supplies for patients already stabilized on the treatment. Be aware that stock availability can change, and sudden spikes in demand may affect continuity of care.

Impact and Recommendations

The ongoing shortage has significant implications for patients, particularly those with type 2 diabetes who rely on Ozempic for blood sugar control. Patients are advised to:

• Verify availability with their pharmacy before their next dose.
• Discuss with their healthcare provider about possible alternatives if Ozempic is unavailable.

For Healthcare Professionals

Healthcare providers are urged to:

• Follow prescribing guidelines closely and prioritize Ozempic for patients who will benefit most from its use.
• Consider switching patients to alternative therapies where appropriate.

Supply Updates

The TGA continues to work with Novo Nordisk and other stakeholders to manage the Ozempic shortage. Updates will be provided as new information becomes available. For the latest supply information, check the Medicine Shortage Reports Database.

Understanding Ozempic

Ozempic is a brand of semaglutide, a GLP-1 agonist used for managing type 2 diabetes. It:

• Is supplied by Novo Nordisk.
• Is administered as a weekly injection.
• Is approved by the TGA for lowering blood sugar in adults with type 2 diabetes.
• Is sometimes prescribed off-label for weight loss, contributing to the shortage.

Why the Shortage Happened

The shortage began in early 2022 when off-label prescribing for weight loss caused an unexpected spike in demand. The manufacturing process for semaglutide is complex, making it difficult to quickly increase supply.

Regulatory Challenges

The TGA cannot regulate off-label prescribing or compel pharmaceutical companies to increase production or list products on the PBS. Their role is to mitigate the impact on patients by approving temporary supplies of alternative semaglutide products from overseas.

Actions Taken by the TGA

To address the shortage, the TGA has:

• Approved temporary supply of overseas semaglutide products.
• Coordinated with wholesalers to ensure fair distribution.
• Engaged with healthcare organizations to prioritize patients most in need.
• Communicated regularly with the public and healthcare professionals about the shortage.

Long-Term Solutions and Future Prospects

The TGA is in ongoing discussions with Novo Nordisk and healthcare organizations to monitor and manage the situation. Efforts are being made to stabilize the supply chain and explore long-term solutions.

For more detailed information, visit the TGA’s Medicine Shortage Reports Database.